Role of P-Glycoprotein on the CNS Disposition of Amprenavir (141W94), an HIV Protease Inhibitor

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Pharmaceutical Research

• Publication date

  1999-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1023/A:1018941328702PMID 10468021
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Amprenavir

  2012cited by this paper
• Review of Antiretroviral Therapy in the Prevention of HIV-Related AIDS Dementia Complex (ADC)

  2012cited by this paper
• Modulation of the Tight Junctions of the Caco-2 Cell Monolayers by H2-antagonists

  2004cited by this paper
• P-glycoprotein and related transporters.

  1998cited by this paper
• Active Apical Secretory Efflux of the HIV Protease Inhibitors Saquinavir and Ritonavir in Caco-2 Cell Monolayers

  1998cited by this paper
• Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor.

  1998cited by this paper
• In vitro blood-brain barrier permeability of nevirapine compared to other HIV antiretroviral agents.

  1998cited by this paper
• HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter.

  1998cited by this paper
• Effect of GF120918, a Potent P-glycoprotein Inhibitor, on Morphine Pharmacokinetics and Pharmacodynamics in the Rat

  1998cited by this paper
• The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.

  1998cited by this paper
• Characterization of phosphine complexes of technetium(III) as transport substrates of the multidrug resistance P-glycoprotein and functional markers of P-glycoprotein at the blood-brain barrier.

  1997cited by this paper
• Visualization of human herpesvirus type 8 in Kaposi's sarcoma by light and transmission electron microscopy

  1997cited by this paper
• Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP.

  1997cited by this paper
• Protease inhibitors: a therapeutic breakthrough for the treatment of patients with human immunodeficiency virus.

  1997cited by this paper
• Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins.

  1997cited by this paper
• Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir

  1997cited by this paper
• The neuropathogenesis of the AIDS dementia complex.

  1997cited by this paper
• HIV protease inhibitors

  1996cited by this paper
• Cyclosporin A treatment induces overexpression of P-glycoprotein in the kidney and other tissues.

  1996cited by this paper
• Age-dependent Expression of P-Glycoprotein gp17O in Caco-2 Cell Monolayers

  1996cited by this paper
• Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy.

  1995cited by this paper
• Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P‐glycoprotein: Implications for drug delivery and activity in cancer chemotherapy

  1995cited by this paper
• In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative.

  1993cited by this paper
• Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites.

  1989cited by this paper

• Strategies to improve nasal administration of antiretroviral therapeutics for the treatment of NeuroAIDS.

  2026cites this paper
• Biophysical and Functional Characterization of a Thermally Stable Bifunctional Serine Protease Inhibitor from Cleome viscosa Seeds

  2025cites this paper
• Regulatory Role of IL6 in Immune-Related Adverse Events during Checkpoint Inhibitor Treatment in Melanoma

  2024cites this paper
• Relevance of ABC Transporters in Drug Development.

  2022cites this paper
• P-glycoprotein: new insights into structure, physiological function, regulation and alterations in disease

  2022cites this paper
• Treating viruses in the brain: Perspectives from NeuroAIDS.

  2021cites this paper
• The HIV protease inhibitor, ritonavir, corrects diverse brain phenotypes across development in mouse model of DYT-TOR1A dystonia

  2021cites this paper
• The Role of P-Glycoprotein at the Blood–Brain Barrier in Neurological and Psychiatric Disease

  2020cites this paper
• Opioid and neuroHIV Comorbidity – Current and Future Perspectives

  2020influential citation
• A Practical Perspective on the Evaluation of Small Molecule CNS Penetration in Drug Discovery.

  2020cites this paper
• Futuristic Methods for Treatment of HIV in the Nervous System

  2019cites this paper
• HIV-1 Tat and opioids act independently to limit antiretroviral brain concentrations and reduce blood–brain barrier integrity

  2019cites this paper
• Bio-analytical Assay Methods used in Therapeutic Drug Monitoring of Antiretroviral Drugs-A Review

  2019cites this paper
• Interactions of protease inhibitors atazanavir and ritonavir with ABCB1, ABCG2, and ABCC2 transporters: Effect on transplacental disposition in rats.

  2018cites this paper
• Structural and Functional Consequences of HIV-1 Viral Protein Tat and Morphine Co-Exposure at the Blood-Brain Barrier

  2018cites this paper
• Utilizing in vitro transporter data in IVIVE-PBPK: an overview

  2017cites this paper
• Antiretroviral Therapy: Brain Penetration

  2017cites this paper
• Intestinal Drug Interactions Mediated by OATPs: A Systematic Review of Preclinical and Clinical Findings.

  2017cites this paper
• Pharmacokinetic characterization of anhuienoside C and its deglycosylated metabolites in rats

  2017influential citation
• Clinical Implications of P-Glycoprotein Modulation in Drug–Drug Interactions

  2017cites this paper
• Factors Contributing to the Antiviral Effectiveness of Tenofovir

  2017cites this paper
• Pharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of Antiretrovirals

  2016cites this paper
• HIV and viral protein effects on the blood brain barrier

  2016cites this paper
• Effect of quercetin on the transport of ritonavir to the central nervous system in vitro and in vivo

  2016cites this paper
• The Role of Metabolizing Enzymes and Transporters in Antiretroviral Therapy.

  2016cites this paper
• Surface modification strategies on mesoporous silica nanoparticles for anti-biofouling zwitterionic film grafting.

  2015cites this paper
• Examining the selectivity in the impact of pulmonary P-gp upon the absorption of its substrates using an IPML model with knockout mice

  2015cites this paper
• Pharmacokinetics and allometric scaling of antimalarial drugs

  2015cites this paper
• Differential role of P-glycoprotein and breast cancer resistance protein in drug distribution into brain, CSF and peripheral nerve tissues in rats

  2015cites this paper
• Do adsorbed drugs onto P-glycoprotein influence its efflux capability?

  2015cites this paper
• HZ08 Reverse P-Glycoprotein Mediated Multidrug Resistance In Vitro and In Vivo

  2015cites this paper
• Lead Optimization of a Pyrazole Sulfonamide Series of Trypanosoma bruceiN-Myristoyltransferase Inhibitors: Identification and Evaluation of CNS Penetrant Compounds as Potential Treatments for Stage 2 Human African Trypanosomiasis

  2014cites this paper
• Lead optimization of a pyrazole sulfonamide series of trypanosoma brucei N myristoyltransferase inhibitors

  2014cites this paper
• Anti-HIV drug conjugates for enhanced mucosal pre-exposure prophylaxis

  2014cites this paper
• Current advances on ABC drug transporters in fish.

  2014cites this paper
• Innovative in vitro method and permeability estimation procedure to predict drug transport across the blood-brain barrier

  2014cites this paper
• Absence of P-Glycoprotein Transport in the Pharmacokinetics and Toxicity of the Herbicide Paraquat

  2014influential citation
• Pregnane X Receptor and P-glycoprotein: a connexion for Alzheimer’s disease management

  2014cites this paper
• A proposed role for efflux transporters in the pathogenesis of hydrocephalus

  2014cites this paper
• FDA Bioequivalence Standards

  2014cites this paper
• Inhibition of P-Glycoprotein by HIV Protease Inhibitors Increases Intracellular Accumulation of Berberine in Murine and Human Macrophages

  2013cites this paper
• P-glycoprotein (P-gp/MDR1)/ABCB1

  2013cites this paper
• Analysis of Hepatic Transport Proteins

  2013cites this paper
• Microglial activation decreases retention of the protease inhibitor saquinavir: implications for HIV treatment

  2013influential citation
• Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption.

  2013cites this paper
• Intestinal First-Pass Metabolism by Cytochrome P450 and Not P-Glycoprotein Is the Major Barrier to Amprenavir Absorption

  2013influential citation
• Advances in brain targeting and drug delivery of anti-HIV therapeutic agents

  2013cites this paper
• The right compound in the right assay at the right time: an integrated discovery DMPK strategy

  2012cites this paper
• Whole‐Body Autoradiography and Microautoradiography in Drug Discovery and Development

  2012cites this paper
• Use of Cassette Dosing Approach to Assess Brain Penetration in Drug Discovery

  2012cites this paper
• Prodrug approaches to reduce hyperexcitation in the CNS.

  2012cites this paper
• Use of antineoplastic agents in cancer patients with HIV/AIDS

  2012cites this paper
• Cobicistat Boosts the Intestinal Absorption of Transport Substrates, Including HIV Protease Inhibitors and GS-7340, In Vitro

  2012cites this paper
• Renal drug–drug interactions: what we have learned and where we are going

  2012cites this paper
• Use of the Cassette-Dosing Approach to Assess Brain Penetration in Drug Discovery

  2012cites this paper
• Toward eradicating HIV reservoirs in the brain: inhibiting P-glycoprotein at the blood-brain barrier with prodrug abacavir dimers.

  2012cites this paper
• Mammalian drug efflux transporters of the ATP binding cassette (ABC) family

  2012cites this paper
• Efflux transporters in the blood–brain interfaces – in vitro and in vivo methods and correlations

  2012cites this paper
• P-Glycoprotein Is a Major Determinant of Norbuprenorphine Brain Exposure and Antinociception

  2012cites this paper
• Assessment of Remogliflozin Etabonate, a Sodium-Dependent Glucose Co-Transporter-2 Inhibitor, as a Perpetrator of Clinical Drug Interactions: A Study on Drug Transporters and Metabolic Enzymes

  2012cites this paper
• Use of antineoplastic agents in patients with cancer who have HIV/AIDS.

  2011cites this paper
• Calcein assay: a high-throughput method to assess P-gp inhibition

  2011cites this paper
• Human immunodeficiency virus therapeutics and pharmacogenomics

  2011cites this paper
• Pharmacological Characterization of a Novel α2C-Adrenoceptor Agonist N-[3,4-dihydro-4-(1H-imidazol-4-ylmethyl)-2H-1, 4-benzoxazin-6-yl]-N-ethyl-N′-methylurea (Compound A)

  2011influential citation
• Mechanisms of Drug Interactions II: Transport Proteins

  2011cites this paper
• The effect of the dynamic interplay of P-glycoprotein and cytochrome P450 3A on the portal bioavailability of dual substrates

  2011influential citation
• In-silico ADME models: a general assessment of their utility in drug discovery applications.

  2011cites this paper
• The Central Nervous System Manifestations of HIV-1 Infection in the Combination Antiretroviral Therapy Era

  2011cites this paper
• Improving delivery of molecularly targeted agents to glioma

  2011cites this paper
• How much do antiretroviral drugs penetrate into the central nervous system?

  2011cites this paper
• Preclinical Pharmacology of the MDM2 Antagonist Nutlin-3a

  2011cites this paper
• Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics

  2011influential citation
• Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up.

  2011cites this paper
• Structural and functional properties of human multidrug resistance protein 1 (MRP1/ABCC1).

  2011cites this paper
• Discovery of a Novel Class of Orally Active Trypanocidal N-Myristoyltransferase Inhibitors

  2011cites this paper
• Concentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 T cells and primary human lymphocytes.

  2010cites this paper
• Pharmacokinetics and Bioavailability of an Integrase and Novel Pharmacoenhancer-Containing Single-Tablet Fixed-Dose Combination Regimen for the Treatment of HIV

  2010cites this paper
• Pure drug and polymer based nanotechnologies for the improved solubility, stability, bioavailability and targeting of anti-HIV drugs.

  2010cites this paper
• The permeability P-glycoprotein: a focus on enantioselectivity and brain distribution

  2010cites this paper
• Anticipating and Minimizing Drug Interactions in a Drug Discovery and Development Setting: An Industrial Perspective

  2010cites this paper
• Evaluation of drug transporter interactions in drug discovery and development.

  2010cites this paper
• Effect of electromagnetic field on endocytosis of cationic solid lipid nanoparticles by human brain-microvascular endothelial cells

  2010cites this paper
• Drug penetration across the blood-brain barrier: an overview.

  2010cites this paper
• Prodrug and conjugate drug delivery strategies for improving HIV/AIDS therapy.

  2009cites this paper
• The transport of anti-HIV drugs across blood–CNS interfaces: Summary of current knowledge and recommendations for further research

  2009cites this paper
• Biopharmaceutics classification system: validation and learnings of an in vitro permeability assay.

  2009cites this paper
• Liver transporters in hepatic drug disposition: an update.

  2009cites this paper
• Clinical implications of antiretroviral pharmacokinetics and pharmacodynamics in the CNS

  2009cites this paper
• Brain as an HIV sequestered site

  2009cites this paper
• Current and Novel Inhibitors of HIV Protease

  2009cites this paper
• Expression and activity of the efflux transporters ABCB1, ABCC2 and ABCG2 in the human colorectal carcinoma cell line LS513.

  2009cites this paper
• Chapter 12- Brain as an HIV sequestered site: Use of nanoparticles as a therapeutic option.

  2009cites this paper
• P-Glycoprotein Efflux Transporter Activity Often Displays Biphasic Dose-Response Relationships

  2008cites this paper
• The Role of Efflux and Uptake Transporters in Lapatinib ( Tykerb , GW 572016 ) Disposition and Drug Interactions

  2008influential citation
• Protease inhibitor plasma concentrations in HIV antiretroviral therapy.

  2008cites this paper
• Applications and limitations of genetically modified mouse models in drug discovery and development.

  2008cites this paper
• Role of transport proteins in drug discovery and development: a pharmaceutical perspective.

  2008cites this paper
• Endothelin-1 Reduces P-Glycoprotein Transport Activity in an In Vitro Model of Human Adult Blood–brain Barrier

  2008cites this paper
• Scaling of in Vitro Membrane Permeability to Predict P-glycoprotein-Mediated Drug Absorption in Vivo

  2008cites this paper
• Chapter 27 – Transporter Methods

  2008cites this paper